



Correspondence

Healthcare professionals & adverse events of ChAdOx1 nCoV-19 coronavirus vaccine

Sir,

We would like to share ideas on the publication entitled "Reporting adverse events of ChAdOx1 nCoV-19 coronavirus vaccine (Recombinant) among the vaccinated health-care professionals: A cross-sectional survey" by Kaur *et al*¹. The authors concluded that "ChAdOx1 nCoV-19 Corona Virus Vaccine was found to be associated could be dealt with oral over-the-counter medications, with no requirement of hospitalization". We agree that any vaccines, including the COVID-19 vaccine, can cause adverse effects. The present report can confirm the safety of COVID-19 vaccine the information on the safety of vaccination should be generalized to reassure both practitioners and general people. Regarding the reported incidence, it should be noted that the exact incidence should be less than that reported. Since there is a possibility of concurrent medical problems or the effect of background personal illness, not all clinical problems after vaccination are the result of vaccination^{2,3}. In addition to the simple report system, there should be additional verification process to gather the final exact data on the adverse effects of the vaccine.

Conflicts of Interest: None.

**Rujittika Mungmunpantipantip^{1,*} &
Viroj Wiwanitkit²**

¹Consultant Unit, Private Academic Consultant, Bangkok, Thailand & ²Department of Community Medicine, Dr. D. Y. Patil University, Pune 411 018, Maharashtra, India

**For correspondence:*
rujittika@gmail.com

Received February 11, 2022

References

1. Kaur S, Singh A, Saini S, Rohilla L, Kaur J, Chandi A, *et al*. Reporting adverse events of ChAdOx1 nCoV-19 coronavirus vaccine (Recombinant) among the vaccinated healthcare professionals: A cross-sectional survey. *Indian J Med Res* 2022; 155 : 123-8.
2. Kebayoon A, Wiwanitkit V. Dengue after COVID-19 vaccination: Possible and might be missed. *Clin Appl Thromb Hemost* 2021. Doi: 10.1177/10760296211047229.
3. Mungmunpantipantip R, Wiwanitkit V. Thrombosis after adenovirus-vectored COVID-19 vaccination: A concern on underlying illness. *Clin Appl Thromb Hemost* 2021. Doi: 10.1177/10760296211060446.